KLKristofoor E. Leeuwenberg

Kristofoor E. Leeuwenberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kristofoor E. Leeuwenberg has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Convergent validity, responsiveness, and meaningful within-subject change of the PROM-Ataxia in spinocerebellar ataxias

    by Kristofoor E. Leeuwenberg, Teije H. van Prooije, Colette Reniers, Kirsten C. J. Kapteijns, Roderick P. P. W. M. Maas, Bart P. van de Warrenburg

    Background: The clinimetric properties of the Patient-Reported Outcome Measure of Ataxia (PROM-Ataxia) have only been partially explored. This study aimed to investigate its convergent validity, responsiveness, and minimal clinically important difference (MCID), as well as its discriminative ability at the earliest disease stages in different types of spinocerebellar ataxia (SCA). Methods: Baseline and 1 year PROM-Ataxia data were obtained from three single-center cohort studies involving ataxic and pre-ataxic SCA1, SCA3, and SCA7 mutation carriers and healthy controls. Spearman correlations were assessed between PROM-Ataxia scores and the Scale for the Assessment and Rating of Ataxia, Inventory of Non-Ataxia Signs, SCA Functional Index, Cerebellar Cognitive Affective Syndrome Scale, 5-level EuroQoL 5-Dimensional Visual Analogue Scale, Patient Health Questionnaire−9, Unified Huntington Disease Rating Scale Part IV, and the Activities of Daily Living subscale of the Friedreich Ataxia Rating Scale. Responsiveness was evaluated using standardized response means (SRM), and MCIDs through anchor-based and distribution-based approaches. Results: Seventy-six mutation carriers (20 SCA1, 40 SCA3, 16 SCA7) were included at baseline, with 68 completing the 1-year follow-up visit. PROM-Ataxia scores correlated moderately to strongly with other measures (ρ=0.46–0.89, p p p =0.048) with considerable between-subject variability of change (SD=22.0) and low responsiveness (SRM=0.17). The MCID of the PROM-Ataxia total score was estimated at 9.8–12.7. Conclusion: PROM-Ataxia already distinguishes pre-ataxic SCA mutation carriers from healthy controls in physical, ADL, and mental health domains, and demonstrates strong convergent validity. Although responsiveness at the group level was somewhat limited because of large interindividual variability, 1 year follow-up scores adequately reflected the individual patient’s global impression of change.

    • 26 May 2026
      • Vol. 170

    [The rise of genetic therapies: urgent moral and societal questions].

    by Kris E Leeuwenberg, Karlien Mul, Bart P van de Warrenburg, Gert Olthuis

    Genetic therapies offer long-awaited hope for patients with rare genetic diseases and are emerging as cancer treatment as well. While these innovations appear promising, they are also extremely expensive and raise concerns about how they fit into an already overburdened healthcare system. What are the societal implications when these treatments become available? And how can we guide their adoption in the Dutch healthcare system in an ethically responsible manner? We describe the emerging landscape of genetic therapies, and specifically examine the ethical concerns surrounding their implementation within the Dutch healthcare system. From this reflection, we seek to offer direction on how to approach these new biomedical developments in a way that preserves the fundamental values of solidarity and justice. This is particularly important, given how rapidly developments in this field are progressing.

  • Prospective Study of Video Hand Opening Time as a Quantitative Measurement of Myotonia in Patients With Myotonic Dystrophy Type 1

    by Kristofoor E. Leeuwenberg, Valeria A. Sansone, Johanna Hamel, Man Hung, Jeanne M. Dekdebrun, Andrea Lizio, Katy Eichinger, Cynthia Gagnon, Richard H. Roxburgh, Sub H. Subramony, et al.

    Delayed grip relaxation is a common symptom of myotonic dystrophy type 1 (DM1), differing from other muscle diseases. Preclinical studies suggest myotonia may reverse quickly with targeted treatment and video hand opening time (vHOT) could be a straightforward method for assessing myotonia in multicenter trials, but few studies have evaluated vHOT in large DM1 cohorts. This study aimed to evaluate how vHOT performs and relates to other disease aspects in a large, well-characterized DM1 population. The vHOT was conducted in the END-DM1 natural history study across 22 international sites, including adult DM1 patients with a genetic or research criteria diagnosis. The primary outcome involved video-recorded hand opening after a maximum 3-second grip, performed twice at each study visit with 5-minute rest between trials, and blinded scoring at a central site. Muscle strength and function were assessed by myometry, timed functional tests, and patient-reported outcomes. Procedures were repeated after 1 year for a subset of participants. Wilcoxon signed-rank was used to evaluate differences and Spearman correlation for associations. A total of 591 patients with DM1 (mean age 43.7 ± 12.9 years, 57% female) were included, showing a broad spectrum of vHOT severity (median 3.9 seconds, interquartile range 1.8-7.9 seconds). At a single study visit, there were no systematic difference and good agreement between trials (mean difference 0.1 ± 3.7 seconds [p = 0.05], intraclass correlation coefficient 0.84 [95% CI 0.81-0.86]). vHOT correlated relatively weak with self-reported myotonia (ρ = 0.39), and even lower for other measures of muscle impairments such as grip strength (ρ = -0.21) or 9-hole pegboard (ρ = 0.12). 270 patients completed the 1-year follow-up, with vHOT showing no progression (mean difference 0.4 ± 4.7 seconds, p = 0.34). The vHOT procedure was performed successfully in a large international study, with grip relaxation delay varying from minimal to highly prolonged in an unselected cohort. The weak correlation with grip weakness supports the notion that myotonia and weakness are mechanistically distinct. Study limitations include underrepresentation of congenital DM1 and lack of other myotonia measures (e.g., handgrip relaxation myometry). It seems that vHOT is not suitable to assess disease progression, but stability over 1 year may support its use to assess improvement. The END-DM1 observational study is registered with number NCT03981575.


  • Open Access

    The goal attainment scale in primary mitochondrial disease: Construct validity and lessons learned from a randomized controlled trial

    by Kristofoor E. Leeuwenberg, Joanna IntHout, Jan T. Groothuis, Edith Cup, Jan Smeitink, Karlien Mul, Mirian C.H. Janssen

  • Open Access

    The evolution of disease criteria in multiple sclerosis: underlying motives and broader implications

    by Kristofoor E. Leeuwenberg, Lennart H. van der Molen, Marianne Boenink, Edo Richard

    Introduction: Disease criteria for multiple sclerosis (MS) have changed significantly over the past three decades. The development of biomarkers, particularly MRI, has played an essential role in this process. These changes can lead to several broader implications, which are not always intended or recognized. However, they can have a major impact on patients, healthcare and society. We investigated the changing disease criteria, explored the underlying motives and discuss their implications. Methods: We identified all publications on MS diagnostic criteria between 1983 and 2024. Through conventional content analysis, we systematically examined the aims of each revision and identified the underlying problems and factors motivating these aims. Furthermore, we assessed the changes made to the content in each revision. Results: Since the transition from the Poser research criteria to the McDonald clinical criteria in 2001, there has been a significant change in the aims of the criteria, which has continued in subsequent McDonald revisions. Two explicit new aims were to integrate MRI into the diagnostic scheme and to reach an earlier diagnosis of MS whenever possible. Furthermore, the emphasis moved towards criteria that are easy to apply in everyday clinical practice, rather than being exclusively for research purposes. This shift is at least partially connected to the emergence of disease-modifying treatments, which have introduced new diagnostic and monitoring needs. Additionally, advancements in MRI research have contributed to this process. As a result, MRI has become central to the diagnostic criteria over the years, while clinical symptoms now play a much smaller role. Discussion: The shift in the criteria has several broader implications. It has a major impact on how MS is conceptualized as a disease and has expanded the disease spectrum to include new terms such as radiologically isolated syndrome (RIS). It also influences our understanding of the natural course of the disease and calls for a careful balance between early diagnosis and misdiagnosis. Awareness of the process of changes and their broader consequences can help balance the benefits and potential negative effects and helps critically frame the decisions of the 2024 revisions.

  • Open Access

    Peripheral and autonomic nervous system involvement in spinocerebellar ataxia type 3: unveiling an invisible burden

    by Kristofoor E. Leeuwenberg, Nens van Alfen, Bart P. van de Warrenburg, Roderick P. P. W. M. Maas

    Background: Neuropathological examinations in spinocerebellar ataxia type 3 (SCA3) have demonstrated peripheral and autonomic nervous system degeneration, but the impact of associated symptoms on genetically affected individuals at different disease stages remains understudied. Objective: To investigate the clinical burden of peripheral and autonomic nervous system involvement in SCA3 mutation carriers across the disease spectrum. Methods: Forty SCA3 mutation carriers, including ten pre-ataxic individuals, completed questionnaires about muscle cramps, neuropathic pain, autonomic symptoms, activities of daily living, and quality of life, and underwent a standardized clinical examination of ataxia and neuropathy severity. Data were compared with 16 healthy controls. Results: All but one of the ataxic and 60% of pre-ataxic individuals experienced muscle cramps at least weekly. Neuropathic pain was reported by 20% of pre-ataxic and 16.7% of ataxic mutation carriers, while the average number of autonomic symptoms in both groups was 2 and 4.7, respectively. Neuropathy severity scores were significantly higher in pre-ataxic and ataxic individuals than in healthy controls and associated with (i) worse self-reported functional status and (ii) clinician-reported ataxia severity. The number of autonomic symptoms was associated with patient-reported impairments in daily life and quality of life. Conclusion: Clinical features of peripheral and autonomic nervous system degeneration are very common in SCA3, may already be observed in pre-ataxic individuals, and independently contribute to patient-reported disease burden and clinician-rated overall ataxia severity.


  • The Goal Attainment Scale in Spinocerebellar Ataxia Type 3: Exploration of Feasibility and Content Validity

    by Kristofoor E. Leeuwenberg, Roderick P.P.W.M. Maas, Bart P. van de Warrenburg


  • Open Access

    The blind men and the elephant: recognising the multisystem symptoms of myotonic dystrophy type 1

    by Kristofoor E. Leeuwenberg, Johanna E. Bruijnes, Llse Karnebeek, Fran Smulders, Sandra Altena-Rensen, Caroline M.L. Gorissen-Brouwers, Sylvia Klinkenberg, Catharina G. Faber, Hilde Braakman, Karlien Mul

    Although myotonic dystrophy type 1 (DM1) is named after its characteristic muscle symptoms, it is in fact a multisystem disorder that can affect many different organs. It is therefore not surprising that this disease can manifest with a myriad of symptoms, depending on the organs involved. The age of onset and severity of symptoms vary widely. Diagnostic delays of more than ten years are common and it’s not unusual for an entire family to be diagnosed only after the birth of a child with a severe phenotype. Knowledge of the spectrum of possible symptoms in DM1 can aid clinicians to recognise this disorder, thereby preventing unnecessary diagnostic delay and facilitating early treatment of disease complications. Here, we present an overview of the potential symptoms of DM1 at different ages, with the aim of raising awareness among healthcare professionals about the recognition of this disabling disease.


  • Open Access

    Polyradiculitis as a Neurological Complication Associated with Adagrasib: A Case Report

    by Kristofoor E. Leeuwenberg, Rob ter Heine, Johanna M.M. Gijtenbeek, Michel M. van Den Heuvel

    Introduction: Adagrasib is an upcoming anticancer treatment for KRAS G12C-mutated non-small-cell lung carcinoma, colorectal cancer and potentially other solid tumors harboring this mutation. It is generally well-tolerated and reports of neurological adverse events so far have been limited. Case Presentation: We present to our best knowledge the first case of a 70-year-old woman who was admitted with polyradiculitis as a treatment-related complication of adagrasib. Symptoms resolved after treatment with prednisone and therapy interruption of adagrasib followed by a permanent dose reduction. After the dose reduction, there was an ongoing effective tumor response at follow-up, and serum concentrations of adagrasib remained within the therapeutic index. Conclusion: Through this case report, we aim to bring attention to the possibility of this side effect, as we believe it is important to be aware of it for future patients undergoing treatment with adagrasib.